Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDDE-crosslinked sodium hyaluronate vs sodium hyaluronate injection for knee osteoarthritis
ChiCTR2600123672Phase 4Recruiting
- Sponsor
- Zhejiang Provincial Hospital of Traditional Chinese Medicine
- Start
- Apr 2026
- Countries
- 1
01
Overview
Phase 4, randomised trial of BDDE-crosslinked sodium hyaluronate in knee osteoarthritis (OA) (2 arms), sponsored by Zhejiang Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Change in WOMAC pain subscale score from baseline at week 24. Started Apr 2026; status: recruiting.
02
Drugs
BDDE-crosslinked sodium hyaluronate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2600123672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123672.